Who is eligible for clinical trial NCT07168785?

Participants must meet the protocol's inclusion criteria for Head and Neck Squamous Cell Carcinoma (HNSCC). The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT07168785 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-21

[18F]-AraG PET Imaging in LA HNSCC (NCT07168785)

[18F]-AraG PET Imaging for Enhanced Risk Stratification and Chemoradiotherapy Response Assessment in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

🟡 Not Yet Recruiting Early Phase1 💊 Investigational Drug / Biologic Sponsor: Indiana University

🩺 Plain-English Summary (8th-Grade Level)

This study will use \[18F\]-AraG PET/CT scans to monitor patients who have been diagnosed with locally advanced Head and Neck Squamous Cell carcinoma (LA-HNSCC), and are planning to undergo standard of care chemoradiotherapy for treatment.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (5 items).

Location: Indiana University — Indianapolis, Indiana

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Patients ≥18 years of age.
Ability to provide written informed consent and HIPAA authorization.
LA-HNSCC in the larynx, hypopharynx, or human papillomavirus (HPV) negative oropharynx and is planning to receive definitive CRT as the SOC treatment, which includes a total of 70 Gy of radiation dose in 35 fractions, delivered over 5 days a week for 7 weeks, as well as planned weekly cycles of cisplatin (CDDP).
Tumor stage III and IV (AJCC 8th edition).
Unresectable cases.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Willing and able to maintain the imaging protocol.
Patients planning to receive pre-CRT and post-CRT FDG PET/CT scans as part of the standard clinical practice.

Usually NOT eligible if any of the following apply:

Exclusion Criteria
Diagnosis of immunodeficiency or receiving systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to the PET/CT scan.
Pregnant or breastfeeding.
Patients that will receive definitive induction chemotherapy or surgery.
Patients who are unable to complete the radiation therapy.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Indiana University — Indianapolis, Indiana

📞 Contact the Study Coordinator

Phone: (317) 962-8969

Email: kilauer@iu.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Head and Neck Squamous Cell Carcinoma (HNSCC)

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Los Angeles, California
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors — Los Angeles, California
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma — Tucson, Arizona
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC — Duarte, California
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer — Pittsburgh, Pennsylvania

Explore by condition: All Head and Neck Squamous Cell Carcinoma (HNSCC) clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗